



# INVESTOR FACT SHEET

**Oxis International, Inc. (OTCBB: OXIS)** is the premier nutraceutical provider for a potent antioxidant, Ergothioneine. Extensive data has been obtained by researchers worldwide on the presence of l-ergothioneine in human tissues. In addition to this potent antioxidant, Oxis also has an extensive patent portfolio and a portfolio of therapeutic compounds.

## Ergothioneine... The Super-Antioxidant

To our knowledge, OXIS remains the only significant commercial source of pure l-ergothioneine worldwide using our patented synthetic manufacturing process. L-ergothioneine is a natural antioxidant amino acid normally found in high concentrations in tissues of the body exposed to high levels of oxidative stress (free-radical damage). Humans and other animals cannot synthesize l-ergothioneine (as is also true for the so-called essential amino acids) therefore we have to obtain it from our diet. An extensive compound monograph has been generated that includes an overview of available data. Synthesized by fungi in the soil, L-ergothioneine can be found in such dietary sources as meats, fruits and vegetables. It has been shown that L-ergothioneine plays a dual role in both energy regulation and in protecting cells from oxidative damage.

## Therapeutics... Targeting Oxidative Damage

Oxidative stress is caused by the unchecked activities of free radicals and reactive oxygen species (ROS). These are highly reactive, unstable molecules that, in healthy cells, are created and neutralized as part of normal cell life. However, if the production of free radicals and ROS exceeds the body's natural defense mechanisms, oxidative damage to vital molecules in the body can occur, leading to cell death.

OXIS' goal has been to control both direct cellular damage from ROS and the activation of certain molecules called transcription factors, which are activated by ROS and trigger inflammatory responses and cell death in degenerative diseases. The company has conducted early stage development of molecules that target different disease indications, including BXT 51072 and Glutathione Mimics, Lipid Soluble Antioxidants, and Superoxide Dismutase (SOD). Further information on each compound (s) is available on our website at [www.oxis.com](http://www.oxis.com).

## Growth Strategy

OXIS prepares to bring a unique compound called Ergothioneine, one of the more powerful antioxidants available, into the highly lucrative nutraceuticals market. With its proprietary method for commercially producing Ergothioneine, OXIS plans to become the primary worldwide source

TRADING STATS*	
Bid: 0.221	Last Price: 0.235
52 Week High: 0.61	52 Week Low: 0.04
Avg. Share Volume: 245,100	
Shares out**: ~47M	

## ERGO PROFILE

### Safety/Toxicity

In vivo, no signs of toxicity as measured by mortality, clinical observation, variation in body weight or hematological and biochemical parameters

### Proprietary Position

U.S. Patent #5,438,151 is a process patent for the synthesis of pure l-(+)-ergothioneine. Issued August, 1995. Patent Assignee, OXIS International, Inc.

### Potential Applications

- Pain relief and joint repair
- Topical anti-aging product for cosmetics
- Tailored for blood pressure regulation
- Clear focus and better memory for seniors

for the molecule. OXIS has tested and commercialized Ergothioneine as a nutraceutical dietary supplement (Ergoplex™). Additionally, several companies, including two major international cosmetics firms, use Ergothioneine as an anti-aging agent in skin-care products. OXIS is working in conjunction with Manor Marketing, West Communications, and Protech Labs to advance Ergoplex™.

For more information, please contact:

**Anthony Cataldo**  
Chief Executive Officer

(310) 860-5184

468 N. Camden Dr., 2nd Floor  
Beverly Hills, CA 92202 USA  
E-mail: [info@oxis.com](mailto:info@oxis.com)

\*As of Jan. 2010 \*\*Shares outstanding listed as of Oct. 2009

Except for the historical information contained herein, the matters discussed in this fact sheet include forward-looking statements. Such statements in this fact sheet, including anticipated efficiencies, future product launch dates, are only predictions and reflect current beliefs and expectations of the Company. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company's business, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance, and continuing demand for the Company's products, the impact of competitive products and pricing, and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's reports with the SEC, including but not limited to the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. The Company undertakes no obligation to revise or update this fact sheet to reflect or circumstances after the date hereof.